Navigation Links
Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
Date:11/6/2007

eases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus and HIV. For further information about Idenix, please refer to http://www.idenix.com.

Forward-looking Statements

This press release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward- looking statements can be identified by the use of forward-looking terminology such as "expect," "may," "plans," "will," or similar expressions, or by express or implied statements with respect to the company's clinical development programs or commercialization activities in HIV or hepatitis C, or any potential pipeline candidates and expectations with respect to additional milestone payments and cash balances at the end of 2007. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantees that historical sales of Tyzeka/Sebivo will in any way suggest future royalty payments or royalty rates owed to the company, or that the company will advance any clinical product candidate or other component of its potential pipeline to the clinic, to the regulatory process or to commercialization. In particular, management's expectations could be affected by unexpected regulatory actions or delays; uncertainties relating to, or unsuccessful results of, clinical trials, including additional data relating to the ongoing clinical trials evaluating its product candidates; the company's ability to obtain additional funding required to conduct its research, development and commercialization activities; the company's dependence on its collaboration with Novartis Pharma AG; changes in the company's business plan or objectives; the ability of the company to attract and ret
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Ashburn, Virginia (PRWEB) July 11, 2014 ASHBURN ... 367 took effect, which allows individuals with an intellectual disability ... back of their licenses and ID cards to alert law ... with a condition. The idea was inspired by a ... proactive in protecting her 9 year old autistic son, JP. ...
(Date:7/10/2014)... consuming a supplement of omega 3 fatty acids had ... fats and omega 6 fatty acids, according to Duke ... Annals of the Rheumatic Diseases (10.1136/annrheumdis-2014-205601) on July ... just obesity may contribute to worsening osteoarthritis. , ... significant role than mechanical factors in the link between ...
(Date:7/10/2014)... Thousands of researchers from more than ... 13-17 to reveal the latest study results, theories ... in dementia science. The Alzheimer’s Association International Conference ... kind. , As part of the Alzheimer’s Association’s ... generating new knowledge about dementia and fostering a ...
(Date:7/10/2014)... City, NY (PRWEB) July 10, 2014 ... life sciences industry, has launched a new website. ... as well as increased access to the firm’s thought ... cbpartners.com provides an ideal platform to showcase our insights, ... access issues,” says CBPartners’ Chief Executive Officer, Cyrus Chowdhury. ...
(Date:7/10/2014)... York (PRWEB) July 10, 2014 ... to protecting the rights of victims injured by ... brought a lawsuit over allegations that the woman’s ... by a power morcellator used during a routine ... filed against Richard Wolf Medical Instruments Corporation over ...
Breaking Medicine News(10 mins):Health News:Recent Special “Autism” Code on Virginia Driver’s Licenses and ID Cards Goes into Law: Helpful or Discriminatory for Individuals on the Autistic Spectrum? 2Health News:Recent Special “Autism” Code on Virginia Driver’s Licenses and ID Cards Goes into Law: Helpful or Discriminatory for Individuals on the Autistic Spectrum? 3Health News:Omega 3 fatty acids lessen severity of osteoarthritis in mice 2Health News:CBPartners Announces New Website 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 3Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 4Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 5
... Parents really need to stop their kids from becoming mini-couch ... dont get regular exercise are at risk of chronic ... of their study, researchers from the British Heart Foundation examined ... secondary schools in Leicester. ,They found that half ...
... conducted by a team of researchers led by Dr Peter ... ,As part of the study, researchers analysed schoolchildren who ... ,Researchers asked their parents about their kids fruit ... ,The study found that although there was no connection between ...
... of climbers have collected half a tonne of junk littered ... Monday . ,The garbage was mostly left behind ... kilos of essential items are hauled up the mountain in ... Ken Noguchi told reporters here that the expedition collected garbage ...
... exercise appears to modestly increase levels of high-density ... meta-analysis study in the issue of Archives of ... high-density lipoprotein cholesterol (HDL-C) is an independent risk ... death worldwide, according to background information in the ...
... Substituting soy nuts for other protein sources in a ... women , and also may reduce cholesterol levels in ... in the issue of Archives of Internal Medicine. ... pressure (hypertension) affects approximately 50 million Americans and 1 ...
... studying the addition of sugars to proteins ... system of insects, Karen Palter, researcher of Temple ... better understand neurodegenerative diseases in humans. Currently, her ... exploring the glycosylation process that could eventually play ...
Cached Medicine News:Health News:Apple Juice may Help to Keep Childhood Asthma at Bay 2Health News:Regular Exercise may Slightly Increase HDL Levels 2Health News:Soy Nuts may Improve Blood Pressure, Cholesterol Levels in Women 2Health News:Nervous Systems of Insects may Offer Clues on Neurodegenerative Diseases 2Health News:Nervous Systems of Insects may Offer Clues on Neurodegenerative Diseases 3
(Date:1/15/2014)... 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will receive ... Journal of Drugs in Dermatology (JDD) at the ... event is January 17-20, 2014, at the Omni Orlando Resort at ... The ODAC is a distinguished event that delivers ...
(Date:1/15/2014)... Fla. , Jan. 15, 2014  In an unprecedented effort to ... TB in ambulances and other transport vehicles, an advanced and portable ... rescue personnel for the first time. In order ... with these deadly pathogens, West Palm Beach ...
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... developing its Symphony® CGM System as a non-invasive, wireless ... F. Doman , Executive Chairman and Interim CEO of ... Markets, Tenth Annual Equity Conference. Mr. ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... 2007 - Accentia,Biopharmaceuticals, Inc. (NASDAQ: ABPI) announced ... Conference that its interim,analysis of the blinded ... the,Fast-Tracked Phase 3 clinical study of SinuNase(TM), ... in,resolution of one or both of the ...
... WIRE)--Jun 28, 2007 - CombinatoRx,Incorporated (NASDAQ: CRXX) ... placebo-controlled clinical trial of,CRx-150 in patients with ... a disease-modifying anti-rheumatic drug,(DMARD) to placebo plus ... the preliminary analysis of this trial, CRx-150 ...
Cached Medicine Technology:Accentia Biopharmaceuticals Announces Favorable Interim Blinded,Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial,for Chronic Sinusitis 2Accentia Biopharmaceuticals Announces Favorable Interim Blinded,Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial,for Chronic Sinusitis 3Accentia Biopharmaceuticals Announces Favorable Interim Blinded,Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial,for Chronic Sinusitis 4CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 2CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 3CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 4CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 5
... Combining the therapeutic benefits of controlled compression ... swelling, and pain. The anatomically designed cuff ... Cryo/Cuffs can be ordered as a single ... tube assembly and insulation disk). The Cooler ...
... designed to comfortably restrict motion of ... motion of the fingers and wrist. ... splint may be trimmed using cast ... gun. One cotton stockinet is included ...
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
Medicine Products: